A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

Inclusion Criteria:

• Age ≥ 18 years to 54 years with a diagnosis of AD according to the American Academyof Dermatology (AAD) Consensus Criteria (2014) present for at least 12 months

• History of inadequate response to topical corticosteroids (TCS) of medium, high, orhigher potency (with or without topical calcineurin inhibitors)

• Subjects with previous systemic treatment for AD are also considered as inadequateresponders to topical treatments and are potentially eligible to be included in thestudy after appropriate washout.

• Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score ≥ 3

Exclusion Criteria:

• Treatment with a biologic product within 12 weeks or 5 half-lives, whichever islonger, prior to Day 1

• Treatment with any of the following medications or therapies within 4 weeks or 5half-lives, whichever is longer, prior to Day 1:

• Systemic corticosteroids

• Systemic immunosuppressants

• Phototherapy

• Janus kinase inhibitors

• Treatment with any of the following medications or therapies within 1 week, prior toDay 1:

• TCS of any potency

• Topical calcineurin inhibitors (TCI)

• Topical Phosphodiesterase-4 inhibitors (PDE4)

• Other topical immunosuppressive agents

• Combination topical agents containing a corticosteroid or calcineurininhibiting component, PDE4 inhibitors, or other topical immunosuppressiveagents

• Treatment with live virus including live attenuated vaccination 12 weeks prior today 1 pre-randomization.

• Treatment with any meningococcal vaccine within 1 year prior to screening, ortreatment with any tetanus-, diphtheria-, or pertussis containing vaccine within 5years prior to screening